Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clovis Oncology, Inc. - Common Stock (NQ:CLVS)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clovis Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Crude Oil Down Over 2%; Outset Medical Shares Spike Higher
U.S. stocks traded lower midway through trading as investors focused on the outcome of the midterm elections. 
Via Benzinga
Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms
Clovis Oncology Inc (NASDAQ: CLVS) posted a Q3 EPS loss of $(0.39), up from $(0.56) a year ago, on sales of $30.66 million, down from $37.92 million. 
Via Benzinga
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies
Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and... 
Via FinancialNewsMedia
Clovis Oncology's Rubraca Hits Primary Goal In Prostate Cancer Settings
 
Via Benzinga
Why Is Clovis Oncology (CLVS) Stock Up Today?
CLVS stock just caught a bid as Clovis advances potential treatment options for men's disease that deserves the medical community's attention. 
Via InvestorPlace
What Is Going on With Clovis Oncology (CLVS) Stock Today?
Shares of CLVS stock are up more than 25% in the past five days, although August's CPI reading is putting a stop to the rally today. 
Via InvestorPlace
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat
From Clovis
Via Business Wire
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress
From Clovis
Via Business Wire
What Is Going on With Xperi (XPER) Stock Today?
Xperi (XPER) stock is falling on Friday after the media company completed a spinoff of itself from its IP licensing business. 
Via InvestorPlace
Why Is Clovis Oncology (CLVS) Stock Up 11% Today?
Clovis Oncology (CLVS) stock is rising higher on Monday following the release of results from a Phase 3 ovarian cancer clinical trial. 
Via InvestorPlace
Why Is Petrobras (PBR) Stock Up 12% Today?
Petrobras (PBR) stock is getting a boost on Monday thanks to a couple of positive bits of news for the Brazilian oil company. 
Via InvestorPlace
TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations
From Clovis
Via Business Wire
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Friday, 9/23, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
XPEV Stock Alert: 7 Things to Know About the New Xpeng G9 SUV
Xpeng (XPEV) stock is on the move Wednesday after the electric vehicle (EV) company revealed its new flagship G9 SUV today. 
Via InvestorPlace
What Is Going on With Clovis Oncology (CLVS) Stock Today?
Clovis Oncology (CLVS) stock is getting a boost on Wednesday as investors react to news of it reaching a two-year clinical supply agreement. 
Via InvestorPlace
Clovis, Isotopia Ink Clinical Supply Pact For Lutetium-177 Used In Its Targeted Cancer Radiation Therapy
 
Via Benzinga
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
From Clovis Oncology, Inc.
Via Business Wire
Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million. 
Via Benzinga
Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! 
Via InvestorPlace
Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session
Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65. 
Via Benzinga
Adobe (ADBE) Stock Slips on Analyst Downgrade
Adobe (ADBE) stock is sliding lower on Monday after the software company was hit with a downgrade from Mizuho analyst Gregg Moskowitz. 
Via InvestorPlace
Clovis Oncology's Flagship Ovarian Cancer Drug Improves Progression-Free Survival As First-Line Maintenance
 
Via Benzinga
Why Is Clovis Oncology Stock Trading Higher Today?
Clovis Oncology Inc (NASDAQ: CLVS) shares are trading higher Monday after the company presented data showing Rubraca as a first-line maintenance treatment improved progression-free survival in advanced... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning and the news moving them. 
Via InvestorPlace
Why Clovis Oncology Is Trading Higher By 14%; Here Are 28 Stocks Moving Premarket
Gainers Aditxt, Inc. (NASDAQ: ADTX) rose 46.1% to $0.2801 in pre-market trading after jumping 37% on Friday. 
Via Benzinga
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups
From Clovis Oncology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.